Latest News
Novartis Presents New Data on Safety and Efficacy of Zolgensma, Including Maintained and Improved Motor Milestones in Older and Heavier Children with SMA
The SMART study supplements a growing body of evidence on the use of Zolgensma in a patient population older and heavier (1.5 – 9.1 years of age) than the […]
Read More ›Celebrate Rare Disease Day with Cure SMA
Today is Rare Disease Day and the rarest day of all, as this year’s occurrence takes place on February 29! In the U.S., spinal muscular atrophy (SMA) affects nearly 9,000 […]
Read More ›Cure SMA Applauds DOT Proposal to Make Air Travel Safer for Wheelchair Users
Today, on Rare Disease Day, U.S. Transportation Secretary Pete Buttigieg and White House officials announced actions the U.S. Department of Transportation (DOT) plans to take to improve air safety for […]
Read More ›Cure SMA Awards $100,000 Grant to Elana Molotsky, PhD, at the Johns Hopkins University School of Medicine
Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in SMA biology. Our Scientific Advisory Board […]
Read More ›Cure SMA Awards $150,000 Grant to Melissa Bowerman, PhD, at Keele University
Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in SMA biology. Our Scientific Advisory Board […]
Read More ›New Report Highlights Caregiving Challenges of Individuals with Spinal Muscular Atrophy
Cure SMA released a national report on National Caregivers Day that chronicles the caregiving challenges experienced by individuals with spinal muscular atrophy (SMA) and recommends state and federal actions to […]
Read More ›